Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

Leiner Looks To Rule Claritin Equivalent Market With Summer Launches

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24

You may also be interested in...



Leiner Loratadine Success In 2004 Positions Firm For Further OTC Growth

Leiner views its OTC sales growth during its first fiscal quarter as representative of the way the company is reshaping its current business strategy to focus more on nonprescription drugs

Leiner Loratadine Success In 2004 Positions Firm For Further OTC Growth

Leiner views its OTC sales growth during its first fiscal quarter as representative of the way the company is reshaping its current business strategy to focus more on nonprescription drugs

Leiner Loratadine Success In 2004 Positions Firm For Further OTC Growth

Leiner views its OTC sales growth during its first fiscal quarter as representative of the way the company is reshaping its current business strategy to focus more on nonprescription drugs
Table

View full table

Related Content

Pink Sheet Pink Sheet HBW Insight Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS096963

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By